Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.
If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.
StrongSupportsHIGH confidence
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, improves metabolic parameters associated with age-related disease by restoring glycemic control and reducing adiposity in the context of type 2 diabetes and obesity.
Why this rating
Supported by Phase 3 RCTs with over 7,700 participants and FDA approval.
Source
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Volodymyr Mavrych et al. · Frontiers in Aging · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →